Carmell Therapeutics plans to acquire Arizona biotech firm for $65M

Carmell Therapeutics Corp. said it plans to have Axolotl Biologix operate as a wholly-owned subsidiary of Carmell should the deal meet regulatory approvals and other conditions.

Baptist Health licenses know-how, grows relationships in international locales

Two new central city housing projects start work

Alamo City Ticker Visiting Teams: Dallas firm purchases 26 acres on Far West Side

Huntington hits milestone for SBA lending – here’s a breakdown by state

Gelt buys Studio City apartments for $76 million from AvalonBay with plans for upgrades

Aequitas recap: Eyes on a high-profile, and captivating, trial

Kaldi’s Coffee Roasting Company opens new location in St. Charles County

House passes Blue Cross and Blue Shield of North Carolina reorganization bill

Carmell Therapeutics plans to acquire Arizona biotech firm for $65M

Previous Advent Therapeutics lands $3M NIH grant to advance therapy to benefit premature infants

Next Former CEO pleads guilty to lying to feds during $40M health care fraud investigation

firststargroup

Kotek touts $500M Oregon housing plan at Leadership Summit

Retirement plans see boost as states mandate IRAs and tax credits lower costs

Norton Healthcare data breach affected more than 2 million people

Houston-based cell therapy company FibroBiologics files to go public

Suggested Posts

What’s next for a famously empty waterfront restaurant space (Access Louisville podcast)

Oahu retail vacancy rates fall in Q3, according to Colliers report

Sunfish Lake estate on peninsula lists for $2.35 million (gallery)

Scorecard: A year ago, a Nashville brewer filed a trademark lawsuit against a Kansas City peer. Here’s where things stand

Greater Washington’s BLCK VC chapter shows how three years of community building can pay off

Daily Digest: SEC drops charges against Ripple execs; Value of S.F. office building plummets by over 80%

MENU

FirstStar Group

More Stories

Cincinnati investment firm fined by regulator

Previous Advent Therapeutics lands $3M NIH grant to advance therapy to benefit premature infants

Next Former CEO pleads guilty to lying to feds during $40M health care fraud investigation

firststargroup

Related Posts

Suggested Posts

MENU

FirstStar Group

More Stories